RxDoctor Payments Data

Amber Quave, MD

Internal Medicine · N Las Vegas, NVNPI 1992265359

Payments from drug & device makers

$426in general payments, 2019–2025

Across 12 payments — averaging $35.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$125
  • Abbott$120
  • Novo Nordisk$88
  • Boehringer Ingelheim$39
  • Pfizer$23
  • E.r. Squibb & Sons, L.L.C.$15
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$426 in reported general payments places this provider in the 60th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$76,272
Medicare patients
281
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$43,371
JanuviaSitagliptin Phosphate20$17,279
EliquisApixaban13$16,991
MounjaroTirzepatide14$16,731
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$9,955
Atorvastatin Calcium226$2,518
Albuterol Sulfate HfaAlbuterol Sulfate48$1,465
Amlodipine Besylate173$1,290
Losartan Potassium58$1,140
Gabapentin61$1,133
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$1,043
Rosuvastatin Calcium37$939
Varenicline Tartrate11$930
Nifedipine ErNifedipine21$899
Lisinopril114$844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$88$43,37143 claims
PfizerEliquis$23$16,99113 claims
Lilly USA, LLCMounjaro$15$16,73114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in N Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →